› Forums › General Melanoma Community › Which is it?
- This topic has 6 replies, 2 voices, and was last updated 10 years, 10 months ago by JC.
- Post
-
- May 30, 2013 at 2:45 pm
It’s so confusing. I read a Duke study (2003) that basically says up to 15% of thin lesions less than 1mm will recur/mestastasize; but, then I put my info into the melanoma outcome calculator and it basically says it “only” shortens my life expectancy by less than a year. Which is it?
It’s so confusing. I read a Duke study (2003) that basically says up to 15% of thin lesions less than 1mm will recur/mestastasize; but, then I put my info into the melanoma outcome calculator and it basically says it “only” shortens my life expectancy by less than a year. Which is it?
- Replies
-
-
- May 30, 2013 at 4:02 pm
It's both – and it makes perfect sense. For the large majority of people with thin primaries, their melanoma will not shorten their lives by a single day. For the few who will die from it, their lives can be shortened by many years. You put it all together and average it, and you get that "less than a year." It's really a meaningless prognostication for any individual.
Best wishes,
Harry
-
- May 30, 2013 at 4:02 pm
It's both – and it makes perfect sense. For the large majority of people with thin primaries, their melanoma will not shorten their lives by a single day. For the few who will die from it, their lives can be shortened by many years. You put it all together and average it, and you get that "less than a year." It's really a meaningless prognostication for any individual.
Best wishes,
Harry
-
- May 30, 2013 at 4:02 pm
It's both – and it makes perfect sense. For the large majority of people with thin primaries, their melanoma will not shorten their lives by a single day. For the few who will die from it, their lives can be shortened by many years. You put it all together and average it, and you get that "less than a year." It's really a meaningless prognostication for any individual.
Best wishes,
Harry
-
- You must be logged in to reply to this topic.